Interview with Dev Ashish Bakshi, Managing Director, Tapasya Engineering Works
One trend we have seen taking place over the years is that, today, Indian machines are far better in quality and in par with international standards, than 15 years ago.…
Biocon is a fully integrated healthcare company that delivers innovative biopharmaceutical solutions. From discovery to development and commercialisation, Biocon has the defining science, cost-effective drug development capabilities and significant manufacturing capacity to move ideas to market.
Leveraging India’s globally competitive cost base and exceptional scientific people resource, Biocon is advancing in-house R&D programs, while also providing custom and clinical research services to international pharmaceutical and biotechnology majors through our subsidiary companies, Syngene and Clinigene.
Biocon has rapidly developed a robust drug pipeline, led by monoclonal antibodies and several other molecules at exciting stages in the biopharmaceutical value chain.
One trend we have seen taking place over the years is that, today, Indian machines are far better in quality and in par with international standards, than 15 years ago.…
PwC is undoubtedly renowned for its strong network of international expertise, but every market still has its own particularities… What is it, that your clients struggle with the most in…
Undeniably, the landscape for CROs has dramatically changed compared to when you started in the 1990s. The idea of having India as a clinical research destination was not mature yet…
There is no doubt that India has become a country of rising opportunities. Can you first elaborate how important India has become for the Group worldwide? India has become very…
If we look back at the conditions under which you founded Biocon in 1978, we see a young woman with a seed capital of only Rs. 10,000 in a garage…
You have already publicly announced that, despite being late in India, Lonza has been increasingly looking into expanding in the Indian market. First of all, what do you think sparked…
Before moving into the company’s strategy, can you give our readers an idea of what role Boehringer Ingelheim India plays within the Group’s worldwide operations? Within the Boehringer Ingelheim Group,…
To start off, can you tell us how you have seen the pharmaceutical industry developing in India? Has the perception of India by big pharma changed over the years? First…
A catalyst of India’s shifting industry dynamics has been the sector’s M&A activity. We already saw majors such as Piramal going to Abbott and Ranbaxy to Daiichi-Sankyo… And while Andrew…
With the recent event “Vibrant Gujarat”, the state of Gujarat aimed to showcase the region’s opportunities and advanced infrastructure, hosting 1,400 delegates from 101 countries as well as several presentations…
You founded Calyx in 1979 with a three-person team. At the time, you were just 21 years old! What was the vision behind the creation of the company? Essentially, the…
You joined Wockhardt in 2000; you became a member of the board in 2006, and were appointed managing director in 2009. The Indian industry has undergone many changes in the…
See our Cookie Privacy Policy Here